Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest BRAF Stories

2012-02-23 11:26:06

Vanderbilt-Ingram Cancer Center researchers helped lead trial Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival. More than half of patients who were treated with the novel drug vemurafenib, known commercially as Zelboraf, responded to treatment and experienced an impressive median overall survival of nearly 16 months...

2012-02-23 10:15:37

Researchers from UCLA's Jonsson Comprehensive Cancer Center, together with scientists from 12 other sites in the United States and Australia, report for the first time that a newly approved drug for patients with metastatic melanoma nearly doubles median survival times, a finding that will change the way this deadly form of skin cancer is treated. The data comes from an international Phase II study of Zelboraf that included 132 patients followed for at least one year. Patients with this...

2012-01-19 10:16:46

Drug used to treat melanoma with 1 mutation sets off a cascade that results in a different type of skin cancer in cells with another mutation Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf®) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer. Now, researchers at UCLA's Jonsson Comprehensive Cancer Center, working with investigators from the Institute of Cancer Research in London, Roche and...

2011-11-22 16:57:25

UNC scientists contribute cell studies and protein expression analysis Researchers from UNC Lineberger Comprehensive Cancer Center are part of a team that has identified a protein, called P-Rex1, that is key to the movement of cells called melanoblasts. When these cells experience uncontrolled growth, melanoma develops. Melanoma is one of the only forms of cancer that is still on the rise and is one of the most common forms of cancer in young adults. The incidence of melanoma in women...

2011-11-22 08:26:20

(Ivanhoe Newswire) — Papillary carcinoma is the most common type of thyroid cancer, and about one fourth of these carcinomas have mutations in the BRAF gene. These mutations are most common in high-grade carcinomas, in particular, the ones that resist standard treatments. According to researchers at Memorial Sloan-Kettering Cancer Center, New York, exploiting the expression of BRAF by the resistant cancers could be a therapeutic advantage. Despite the prevalence of BRAF mutations in...

2011-11-21 23:09:28

Papillary carcinoma is the most common form of thyroid cancer. Approximately one quarter of these carcinomas have mutations in the BRAF gene. The prevalence of such mutations is even greater in high-grade carcinomas, particularly those that are refractory to standard treatment, which is radioactive iodine (RAI). A team of researchers led by James Fagin, at Memorial Sloan-Kettering Cancer Center, New York, has now identified a way to potentially exploit the expression of BRAF by such cancers...

2011-11-15 21:15:41

Researchers have developed a new genetic screening tool that will aid in the investigation of possible treatments for patients with melanoma and the unique genetic mutations that may accompany the disease, according to data presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011. Heinz-Herbert Fiebig, M.D., Ph.D., associate professor of medical oncology at the University of Freiburg in Germany, presented data from 25...

2011-11-14 15:24:49

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma. The studies, presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011, further elucidated...

1bba6e6ced73cce47ad966bbae6ea6d3
2011-08-18 10:55:00

The US Food and Drug Administration (FDA) on Wednesday approved the cancer treatment drug Zelboraf, used to treat patients with late-stage or unresectable melanoma, the most dangerous form of skin cancer. The drug specifically treats patients with melanoma whose tumors express a gene mutation called BRAF V600E. The drug has not been tested on patients whose melanoma tests negative for the mutation by an approved FDA diagnostic. Zelboraf is being approved with a test called the cobas 4800...

2011-08-17 09:34:00

Decision Opens New Doors to Long-Awaited Combination Trials WASHINGTON, Aug. 17, 2011 /PRNewswire-USNewswire/ -- Melanoma patients who have long faced a bleak treatment landscape are gaining a new approach for treating the deadliest form of skin cancer. The Food and Drug Administration today announced the approval of Zelboraf, known as vemurafenib or PLX4032 during testing, well ahead of the approval deadline. Zelboraf is the first drug to treat advanced melanoma by targeting a specific...